According to FutureWise analysis the market for intravenous pegloticase in 2025 is US$ 4.13 billion, and is expected to reach US$ 12.38 billion by 2033 at a CAGR of 14.71%. The strong market growth is fueled by the rising prevalence of chronic gout, higher diagnosis rates, and limited treatment options for resistant cases. Increased adoption of biologic therapies, better infusion protocols, and combination strategies are supporting this expansion. Additionally, heightened clinician awareness of early intervention in severe cases is boosting the use of intravenous pegloticase.
Intravenous pegloticase is an advanced biologic therapy specifically designed for the treatment of chronic, refractory gout, which is a severe form of gout that does not respond adequately to standard urate-lowering therapies. Gout is characterized by persistently elevated levels of uric acid in the blood, resulting in the formation of monosodium urate crystals that can accumulate in joints and soft tissues. This accumulation can lead to recurrent flare-ups, joint damage, the formation of tophi, and a significant decline in the quality of life for affected individuals.
Pegloticase serves an important clinical need by providing a rapid and effective means of lowering uric acid levels in patients with difficult-to-manage gout. It is a recombinant, pegylated version of the enzyme uricase, which functions to convert uric acid into allantoin—a compound that is more soluble and can be easily excreted by the kidneys. Since humans do not produce functional uricase, pegloticase is particularly beneficial for patients suffering from severe hyperuricemia.
The pegylation process enhances the drug’s half-life and minimizes the body's immune response, thereby allowing for prolonged therapeutic effects when it is administered intravenously. Typically, pegloticase is infused every two weeks, facilitating a rapid reduction of urate levels and potentially leading to the resolution of tophi and improved joint function.
Pegloticase is mainly indicated for patients who have either been intolerant to or have not responded adequately to standard oral treatments, such as xanthine oxidase inhibitors. It is particularly useful in advanced cases of gout, where uncontrolled symptoms significantly disrupt daily functioning. However, due to the potential risk of infusion reactions and the development of antibodies against the drug, careful patient selection, monitoring of serum uric acid levels, and administration in controlled settings are essential when using pegloticase.
With an increasing awareness of refractory gout and advancements in biologic drug development and infusion-based treatments, intravenous pegloticase has gained importance in clinical practice. As treatment approaches continue to evolve, pegloticase represents a valuable therapeutic option that can provide significant disease control for patients with severe and treatment-resistant gout.
FutureWise Market Research has published a report that provides an insightful analysis of Intravenous Pegloticase Market trends that are affecting the overall market growth.
Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=12647&type=requestsample
Intravenous Pegloticase Market Segmentation:
By Age Group
- Pediatric
- Adult
- Geriatric
By Indication
- Chronic
- Refractory
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Competitive Landscape in Intravenous Pegloticase Market:
- Horizon Therapeutics
- BTG plc.
- Savient Pharmaceuticals Inc.
- Takeda Pharmaceutical Company Limited
- Teijin Pharma Limited
- Selecta Biosciences, Inc.
- Krystal Biotech, Inc.
- Medexus Pharmaceuticals, Inc.
- Sobi, Inc. (Swedish Orphan Biovitrum AB)
- Amneal Pharmaceuticals LLC
Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=12647&license=multi
**Objectives of this Study: **
- To provide a comprehensive analysis of the Intravenous Pegloticase Market By Age Group, By Indication, By Distribution Channel and By Region.
- To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
- To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
- To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Flexible Delivery Model:
- We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
- The customization services offered are free of charge with the purchase of any license of the report.
- You can directly share your requirements/changes to the current table of contents to: [email protected]
